Fulgent Pharma, a subsidiary of Fulgent Genetics, will present Phase 1 clinical data on FID-007, its lead therapeutic candidate for head and neck cancer, at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2024.
FID-007 is a nanoparticle formulation of paclitaxel designed to improve drug delivery and tolerability. The formulation employs a polyethyloxazoline (PEOX) polymer excipient, allowing the drug to remain in solution and preferentially target tumor cells through hyperpermeable blood vessels.
Fulgent Pharma emerged from Fulgent LLC in 2016 and was acquired by Fulgent Genetics in 2022. Today, the company focuses solely on developing innovative cancer therapeutics. To advance its research, Fulgent Pharma collaborates with leading institutions such as the University of Southern California, Moffitt Cancer Center, and ANP Technologies.
The FID-007 clinical data will be presented in a poster session on June 2, 2024, from 9:00 a.m. to 12:00 p.m. Central Time. The presentation title is “Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.” The abstract number is 6042, and the poster board number is 345.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
